Salicylates_NNS
inhibit_VBP
lipopolysaccharide-induced_JJ
transcriptional_JJ
activation_NN
of_IN
the_DT
tissue_NN
factor_NN
gene_NN
in_IN
human_JJ
monocytic_JJ
cells_NNS
._.

Binding_NN
of_IN
plasma_NN
Factor_NN
VII\/VIIa_NN
to_TO
the_DT
tissue_NN
factor_NN
-LRB-_-LRB-
TF_NN
-RRB-_-RRB-
receptor_NN
initiates_VBZ
the_DT
coagulation_NN
protease_NN
cascades_NNS
._.

TF_NN
expression_NN
by_IN
circulating_VBG
monocytes_NNS
is_VBZ
associated_VBN
with_IN
thrombotic_JJ
and_CC
inflammatory_JJ
complications_NNS
in_IN
a_DT
variety_NN
of_IN
diseases_NNS
._.

Transcriptional_JJ
activation_NN
of_IN
the_DT
human_JJ
TF_NN
gene_NN
in_IN
monocytic_JJ
cells_NNS
exposed_VBN
to_TO
bacterial_JJ
lipopolysaccharide_NN
-LRB-_-LRB-
LPS_NN
-RRB-_-RRB-
is_VBZ
mediated_VBN
by_IN
binding_NN
of_IN
c-Rel_NN
\/_:
p65_NN
heterodimers_NNS
to_TO
a_DT
kappa_NN
B_NN
site_NN
in_IN
the_DT
TF_NN
promoter_NN
._.

Here_RB
,_,
we_PRP
report_VBP
that_IN
a_DT
family_NN
of_IN
anti-inflammatory_JJ
agents_NNS
,_,
known_VBN
as_IN
the_DT
salicylates_NNS
,_,
inhibited_VBD
LPS_NN
induction_NN
of_IN
TF_NN
activity_NN
and_CC
TF_NN
gene_NN
transcription_NN
in_IN
human_JJ
monocytes_NNS
and_CC
monocytic_JJ
THP-1_NN
cells_NNS
at_IN
clinically_RB
relevant_JJ
doses_NNS
._.

Furthermore_RB
,_,
sodium_NN
salicylate_NN
blocked_VBD
the_DT
LPS-induced_JJ
proteolytic_JJ
degradation_NN
of_IN
I_NN
kappa_NN
B_NN
alpha_NN
,_,
which_WDT
prevented_VBD
the_DT
nuclear_JJ
translocation_NN
of_IN
c-Rel_NN
\/_:
p65_NN
heterodimers_NNS
._.

In_IN
contrast_NN
,_,
two_CD
other_JJ
nonsteroidal_JJ
anti-inflammatory_JJ
drugs_NNS
,_,
ibuprofen_NN
and_CC
indomethacin_NN
,_,
did_VBD
not_RB
inhibit_VB
LPS_NN
induction_NN
of_IN
the_DT
TF_NN
gene_NN
._.

These_DT
results_NNS
indicated_VBD
that_IN
salicylates_NNS
inhibited_VBD
LPS_NN
induction_NN
of_IN
TF_NN
gene_NN
transcription_NN
in_IN
monocytic_JJ
cells_NNS
by_IN
preventing_VBG
nuclear_JJ
translocation_NN
of_IN
c-Rel_NN
\/_:
p65_NN
heterodimers_NNS
._.

The_DT
clinical_JJ
benefits_NNS
of_IN
salicylates_NNS
in_IN
the_DT
treatment_NN
of_IN
several_JJ
diseases_NNS
,_,
including_VBG
atherosclerosis_NN
and_CC
rheumatoid_JJ
arthritis_NN
,_,
may_MD
be_VB
related_JJ
to_TO
their_PRP$
ability_NN
to_TO
reduce_VB
monocyte_NN
gene_NN
expression_NN
._.

